4th Quarter - Report
ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.
Income
—
Expenses
$275,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Comprehensive Tax Reform proposals Patent Box proposals Orphan Drug Tax Credit R&D Tax Credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| VANESSA PROCTER | — |
| HEIDI L WAGNER | — |
Health Issues HCR
ACA Implementation issues, including health exchanges, biosimilars Track & Trace; pharmaceutical compounding Implementation legislation 340B issues Budget/Sequester issues impacting Medicare/Medicaid (SGR) and FDA user fees
| Lobbyist | Covered position, as disclosed |
|---|---|
| VANESSA PROCTER | — |
| HEIDI L WAGNER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.